3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Nasopharyngeal Carcinoma
39
Carcinoma, Non-Small-Cell Lung
30
Esophageal Squamous Cell Carcinoma
23
Carcinoma, Hepatocellular
21
Triple Negative Breast Neoplasms
18
Squamous Cell Carcinoma of Head and Neck
17
Breast Neoplasms
17
Advanced Solid Tumor
17
Stomach Neoplasms
14
Melanoma
14
Small Cell Lung Carcinoma
13
Colorectal Neoplasms
13
Uterine Cervical Neoplasms
12
Neoplasms
10
Carcinoma, Transitional Cell
10
Carcinoma, Renal Cell
10
Recurrence
9
Head and Neck Neoplasms
8
Solid Tumor
7
Sarcoma
7
Neoplasm Metastasis
7
Liver Neoplasms
7
Urinary Bladder Neoplasms
5
Rectal Neoplasms
5
Esophageal Neoplasms
5
Advanced Solid Tumors
5
Pancreatic Neoplasms
4
Nasopharyngeal Neoplasms
4
Laryngeal Neoplasms
4
Hypopharyngeal Neoplasms
4
Interventions
pembrolizumab
2
toripalimab
1
sintilimab
1
pemigatinib
1
osimertinib
1
durvalumab
1
Vinorelbine
1
Platinum Compounds
1
Nivolumab
1
Ipilimumab
1
Drug Therapy
1
AZD 6244
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Advanced Non Small Cell Lung Cancer
×
toripalimab
×
Clear all
NCT04144608
2024-08-09
TOGATHER
Hunan Province Tumor Hospital
Phase 2
Completed
40 enrolled